Fenfen Peng1, Xi Xia1, Feng He1, Zhijian Li1, Fengxian Huang2, Xueqing Yu1. 1. Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China Key Laboratory of Nephrology, Ministry of Health, Guangzhou, China. 2. Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China Key Laboratory of Nephrology, Ministry of Health, Guangzhou, China hfxyl@163.net.
Abstract
OBJECTIVE: To explore the effect of glycated hemoglobin (HbA1c) and albumin-corrected glycated serum proteins (Alb-GSP) on the mortality of diabetic patients receiving continuous peritoneal dialysis (PD). METHODS: In this single-center retrospective cohort study, incident diabetic PD patients from January 1, 2006, to December 31, 2010, were recruited, and followed up until December 31, 2011. The effect of HbA1c and Alb-GSP on mortality was evaluated by Cox proportional hazards models. RESULTS: A total of 200 patients (60% male, mean age 60.3 ± 10.6 years) with a mean follow-up of 29.0 months (range: 4.3 - 71.5 months) were recruited. Sixty-four patients died during the follow-up period, of whom 21 died of cardiovascular disease (CVD). Mean values for HbA1c, GSP and Alb-GSP were 6.7% (range: 4.1 - 12.5%), 202 μmol/L (range: 69 - 459 μmol/L), and 5.78 μmol/g (range: 2.16 - 14.98 μmol/g), respectively. The concentrations of GSP and Alb-GSP were closely correlated with HbA1c (r = 0.41, p < 0.001 and r = 0.45, p < 0.001, respectively). In multivariate Cox proportional hazards models, patients with HbA1c ≥ 8% were associated with increased risk of all-cause mortality (hazard ratio [HR] = 2.29, 95% confidence interval [CI]: 1.06 - 4.96, p = 0.04), but no increased mortality in patients with 6.0% ≤ HbA1c ≤ 7.9%. Patients with Alb-GSP ≤ 4.50 μmol/g had increased all-cause and non-cardiovascular mortality (HR = 2.42, 95% CI: 1.13 - 5.19, p = 0.02; and HR = 2.98, 95% CI: 1.05 - 8.48, p = 0.04 respectively). CONCLUSIONS: Increased HbA1c and decreased Alb-GSP may be associated with poorer survival in diabetic PD patients, with a non-significant trend observed for poorer survival with the highest level of Alb-GSP.
OBJECTIVE: To explore the effect of glycated hemoglobin (HbA1c) and albumin-corrected glycated serum proteins (Alb-GSP) on the mortality of diabeticpatients receiving continuous peritoneal dialysis (PD). METHODS: In this single-center retrospective cohort study, incident diabetic PDpatients from January 1, 2006, to December 31, 2010, were recruited, and followed up until December 31, 2011. The effect of HbA1c and Alb-GSP on mortality was evaluated by Cox proportional hazards models. RESULTS: A total of 200 patients (60% male, mean age 60.3 ± 10.6 years) with a mean follow-up of 29.0 months (range: 4.3 - 71.5 months) were recruited. Sixty-four patients died during the follow-up period, of whom 21 died of cardiovascular disease (CVD). Mean values for HbA1c, GSP and Alb-GSP were 6.7% (range: 4.1 - 12.5%), 202 μmol/L (range: 69 - 459 μmol/L), and 5.78 μmol/g (range: 2.16 - 14.98 μmol/g), respectively. The concentrations of GSP and Alb-GSP were closely correlated with HbA1c (r = 0.41, p < 0.001 and r = 0.45, p < 0.001, respectively). In multivariate Cox proportional hazards models, patients with HbA1c ≥ 8% were associated with increased risk of all-cause mortality (hazard ratio [HR] = 2.29, 95% confidence interval [CI]: 1.06 - 4.96, p = 0.04), but no increased mortality in patients with 6.0% ≤ HbA1c ≤ 7.9%. Patients with Alb-GSP ≤ 4.50 μmol/g had increased all-cause and non-cardiovascular mortality (HR = 2.42, 95% CI: 1.13 - 5.19, p = 0.02; and HR = 2.98, 95% CI: 1.05 - 8.48, p = 0.04 respectively). CONCLUSIONS: Increased HbA1c and decreased Alb-GSP may be associated with poorer survival in diabetic PDpatients, with a non-significant trend observed for poorer survival with the highest level of Alb-GSP.
Authors: David E Goldstein; Randie R Little; Rodney A Lorenz; John I Malone; David M Nathan; Charles M Peterson Journal: Diabetes Care Date: 2003-01 Impact factor: 19.112
Authors: Christopher J Hill; Alexander P Maxwell; Christopher R Cardwell; Barry I Freedman; Marcello Tonelli; Masanori Emoto; Masaaki Inaba; Yasuaki Hayashino; Shunichi Fukuhara; Tomonari Okada; Christiane Drechsler; Christoph Wanner; Anna Casula; Amanda I Adler; Claudia Lamina; Florian Kronenberg; Elani Streja; Kamyar Kalantar-Zadeh; Damian G Fogarty Journal: Am J Kidney Dis Date: 2013-08-16 Impact factor: 8.860
Authors: K Nunoi; T Kodama; Y Sato; M Iwase; H Yoshizumi; H Kurimoto; H Nishitani; S Nakamura; M Fujishima Journal: Metabolism Date: 1991-09 Impact factor: 8.694